



شرکت تحقیقاتی بیوفارماسی پارس (سهامی خاص)

ثبت شده به شماره ۱۰۰۷۷۲- دارای پروانه تحقیق شماره ۶۰۰۰۱-۸۱۵۸۶

Title:	A randomized, open label, two sequences, single dose, bioequivalence study of Rosuvastatin 40mg tablet of Cosar Pharm Co., IRAN in comparison of Crestor® 40mg tablet of Astra-Zeneca, in 24 healthy adult subjects under fasting conditions
Sponsor:	Cosar Pharm Co., IRAN
Investigational Products:	Rosuvastatin 40mg tablet – Cosar Pharm Co. Crestor 40mg tablet – Astra Zeneca
Project Code:	IR.ZAUMS.REC.1399.198
Principle Investigator:	Ladan Tayebi
Executive Colleagues:	H. Ghaznavi; M. Firoozkouhi Moghadam; M. Hadizadeh; F. Khanalipour; H. Mashhadi A. Esfahani; Sh. Bohlooli
Clinical:	Core Research Lab. of Zahedan University of Medical Sciences
Bio-Analytical Pharmacok. & Statistics:	Pars Biopharmacy Research Co. Chemistry & Chemical Engineering Research Center of Iran
Number of Subjects:	22 healthy adult subjects
Regimen & Duration of Treatment:	- Single dose of 40mg Rosuvastatin tablet - Washout period: At least 7 days
Blood Sampling Points:	Before and at 1.0, 2.0, 3.0, 4.0, 4.5, 5.0, 6.0, 7.0, 8.0, 10.0, 24.0 and 48.0 hours post-dose.
Criteria for Evaluation:	- Efficacy: AUC_{0-48} , $AUC_{0-\infty}$, C_{max} , T_{max} , K_e and $T_{1/2}$ - Safety: Adverse events
Criteria for Bioequivalence:	90% Confidence Intervals of the ratio (T/R)
Conclusion:	- Both formulations had no Serious Adverse Events - The mean ratios of the test to reference product (T/R) of rosuvastatin were respectively 101.79% for AUC_{0-48} and 106.21% for C_{max} . - The 90% confidence intervals calculated for AUC_{0-48} and C_{max} values were within the limits of 80 – 125%.
Final Report Date:	Aug. 2022
This study was approved by Iran Food and Drug Administration	